vesicle amine transport 1Genealiases: MIB · VAT-1 · VATI
Q-omics provides the consensus-scored VAT1 profile across patient tissues and cancer cell-line models. VAT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VAT1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, VAT1 protein abundance shows 27,213 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where VAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VAT1 survival associations across molecular data types. VAT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VAT1 RNA expression–survival associations across cancer types. High VAT1 expression shows unfavorable associations in MESO, OV, LIHC, LGG and LUSC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for VAT1 RNA expression.
This table summarizes VAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VAT1 shows lower tumor expression in KICH and LUAD and higher tumor expression in KIRC, KIRP, THCA and LIHC. The KIRC box plot shows higher VAT1 RNA expression in tumor versus normal tissue (log2 FC = +1.154, t-test p < 0.001).
This table shows molecular features associated with VAT1 in patient tissues and cancer cell lines. In patient samples, VAT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, VAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
